Amgen Inc. reported on Tuesday that its GAAP net income came in at $1.6 billion in the fourth quarter of fiscal 2022, falling 15% from the same three-month period in 2021. GAAP earnings per share (EPS) stood at $3, down 11% year over year and operating income landed at $2.23 billion after declining 3%. Total revenues were $6.83 billion, almost unchanged from the final quarter of 2021.
Full-year results for 2022 showed that total revenues, operating income and net income rose by 1%, 25% and 11% from 2021 and reached $26.3 billion, $9.57 billion and $6.55 billion, respectively. EPS amounted to $12.11 in 2022, up 18% compared to 2021.
The acquisition of Horizon Therapeutics is expected to close in the first half of 2023, Amgen CEO Robert Bradway confirmed. Amgen's shares were 0.55% down in extended trading after the report was published.
